SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Speakers
Javier Morales, MD, FACP, FACE
Clinical Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine At
Hofstra/Northwell University
Vice President
Advanced Internal Medicine Group, P.C.
East Hills, NY

Mark Stolar, MD
Associate Professor of Clinical Medicine
Feinberg School of Medicine
Northwestern University
Chicago, IL

Davida F. Kruger, MSN, APN-BC, BC-ADM
Certified Nurse Practitioner Henry Ford Health System Division of Endocrinology, Diabetes, Bone and Mineral Disease
Detroit, MI

Medical Writer
Josh Kilbridge, President
Kilbride Associates
San Francisco, CA

Title
: A Case-based Exercise in Getting Comfortable with Insulin Therapy
Activity/Course #:
: RealCME2164
Cost:
: Free
Release/Start Date:
: Dec 20 2018
Expiration Date:
: Dec 19 2019
Topics:
: Primary Care Medicine
Target Audience:
: Primary Care Providers
Format:
: RealCME
Estimated Time To Complete CME Activity:
: 1.0 Hour
Credit(s):
: 1.0 AMA PRA Category I Credit(s)
1.0 AANP Contact hour(s) which includes 0.75 pharmacology hour(s)
Hardware/Software Requirements:
Program Summary
Type 2 diabetes mellitus (T2DM) is a major cause of morbidity and mortality in the United States, and its prevalence has been increasing. The disease is characterized by progressive failure of pancreatic β-cell function, leading to increasing difficulty in maintaining glycemic control. Even with multiple oral antidiabetic drugs, many patients need insulin therapy to achieve and maintain glycated hemoglobin (HbA1C) targets.

Early initiation of insulin therapy can reduce morbidity in patients with T2DM, but in practice, insulin therapy is underused. Using video clips taken from a live studio broadcast presented as part of Emerging Challenges in Primary Care 2018, this activity will identify the barriers of clinicians and patients for early initiation of insulin therapy, the current available basal and ultrabasal insulins, and how to develop strategies for initiation and intensification of therapies and improve patient adherence.

Learning Objectives
After completing this program participants should be able to:

  1. Identify the barriers between clinicians and patients to discussing and initiating earlier insulin therapy for diabetes management.
  2. Discuss currently available basal and ultrabasal insulins and their pharmacokinetic/ pharmacodynamic profiles.
  3. Describe how best to initiate, utilize and intensify insulin therapy in patients with diabetes while incorporating treatment guidelines and unique patient needs.
  4. Integrate strategies to improve the patient experience with, and adherence to, insulin therapy.
 
To Obtain CME Credits
  1. Read the learning objectives and faculty disclosures.
  2. Participate in the activity.
  3. Complete the post-test and activity evaluation.
  4. Physicians who successfully complete the post-test and evaluation will receive CME credit.
  5. Nurse Practitioners who successfully complete the post-test and evaluation will receive AANP CE credit.
  6. You must score 60% or higher on the post-test to receive credit for this activity.
  7. All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.0 contact hour of continuing education which includes 0.75 pharmacology hours.
Faculty Disclosure Policy
It is the policy of the National Association for Continuing Education to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speakers
Javier Morales, MD, FACP, FACE serves on the speakers bureau and as a consultant for Lilly, Novo Nordisk, Janssen, and Abbott.

Mark Stolar, MD serves on the speakers bureau for AstraZeneca.

Davida F. Kruger, MSN, APN-BC, BC-ADM serves on the advisory board for Novo Nordisk, Abbott, Eli Lilly and Company, Sanofi Adventis, Janssen, Dexcom, and Intarcia. Davida also serves on the speakers bureau for Janssen, Valeritas, AZ, BI/Lilly, Novo Nordisk, Dexcom, Lilly, Abbott, and Insulet. Additionally, she serves on the grants research team for AZ, Eli Lilly, Novo Nordisk, Hemsley Foundation, Dexcom, Lexicon, Abbott and has stock in Dexcom.


Activity Planning Committe
Gregg Sherman, MD, has no real or apparent conflicts of interest to report.

Sandy Bihlmeyer, M.Ed., has no real or apparent conflicts of interest to report.

Michelle Frisch, MPH, CHCP , has no real or apparent conflicts of interest to report.

Sheila Lucas, CWEP, has no real or apparent conflicts of interest to report.

Harvey Parker, PhD, has no real or apparent conflicts of interest to report.

Josh Kilbridge has no real or apparent conflicts of interest to report.
Commercial Support
This educational activity is supported by an educational grant from Sanofi US.